Health ProductsDear Healthcare Professional Letter

Important Safety Information Regarding Intracranial Hemorrhage in Patients Receiving Aptivus (tipranavir) Capsules - For Health Professionals

· Published by Health Canada · Official notice

Details

Alert type: Dear Healthcare Professional Letter
Category: Drugs
Audience: Healthcare Professionals
Department: Health Canada
Get told about the next health product recall.

We email or text you when Canada issues a recall that matches what you watch: a brand, a product, an allergen. Most never make the news.

Get health product recall alerts

CA$3.99/mo · cancel anytime

Details

This is duplicated text of a letter from Boehringer Ingelheim (Canada) Ltd. Contact the company for a copy of any references, attachments or enclosures.

Notice about Health Canada advisories

Health Canada Endorsed Important Safety Information on Aptivus (tipranavir)

June 29, 2006

Dear Health Care Professional,

Subject: Important Safety Information: Intracranial Hemorrhage in Patients Receiving Aptivus® (tipranavir) Capsules

Boehringer Ingelheim (Canada) Ltd., following discussion with Health Canada, is writing to inform you of important new safety information for APTIVUS. APTIVUS co-administered with low dose ritonavir is indicated for combination antiretroviral treatment of HIV-1 infected adult patients with evidence of viral replication, who are treatment experienced and have HIV-1 strains resistant to multiple protease inhibitors.

  • As of June 7, 2006, Boehringer Ingelheim (BI) has received 14 reports of intracranial hemorrhage (ICH), including 8 fatalities, in 6840 HIV-1 infected patients receiving APTIVUS in clinical trials.
  • Many of the patients experiencing ICH in the APTIVUS clinical trials had other medical conditions (CNS lesions, head trauma, neurosurgery, coagulopathy, hypertension or alcohol abuse) or were receiving concomitant medications, including anticoagulants and antiplatelet agents, that may have caused or contributed to these events.
  • Tipranavir has been observed to inhibit human platelet aggregation in in vitro experiments at levels consistent with concentrations observed in patients receiving APTIVUS/ritonavir.
  • No pattern of abnormal hematologic or coagulation parameters which might predict increased risk of intracranial hemorrhage has been observed in patients preceding the development of ICH.
  • APTIVUS/ritonavir should therefore be used with caution in patients who may be at risk for increased bleeding from trauma, surgery or other medical conditions, or who are receiving medications known to increase the risk of bleeding, including antiplatelet agents or anticoagulants.

Boehringer Ingelheim (Canada) Ltd. is currently working with Health Canada to revise the Warnings and Precautions, and Consumer Information sections of the APTIVUS Product Monograph.

A copy of this Dear Health Care Professional Letter will be posted on Boehringer Ingelheim’s (www.boehringer-ingelheim.ca) web site.

Managing marketed health product-related adverse reactions depends on health care professionals and consumers reporting them. Reporting rates determined on the basis of spontaneously reported post-marketing adverse reactions are generally presumed to underestimate the risks associated with health product treatments. Any case of intracranial hemorrhage or other serious or unexpected adverse events in patients receiving APTIVUS should be reported to Boehringer Ingelheim (Canada) Ltd. or Health Canada at the following addresses:

Boehringer Ingelheim (Canada) Ltd.
Manager, Drug Safety
5180 South Service Road
Burlington, Ontario L7L 5H4
Or call toll free at 1-800-263-5103 Ext. 4603
Or Fax at: 905-333-4464

Any suspected adverse reaction can also be reported to:
Canadian Adverse Drug Reaction Monitoring Program (CADRMP)
Marketed Health Products Directorate
HEALTH CANADA
Address Locator: 0701C
OTTAWA, Ontario, K1A 0K9
Tel: (613) 957-0337 or Fax: (613) 957-0335
To report an Adverse Reaction, consumers and health professionals may call toll free:
Tel: 866 234-2345
Fax: 866 678-6789
cadrmp@hc-sc.gc.ca

The AR Reporting Form and the AR Guidelines can be found on the Health Canada web site or in The Canadian Compendium of Pharmaceuticals and Specialties.

For other inquiries related to this communication, please contact Health Canada at:
Bureau of Gastroenterology, Infection and Viral Diseases (BGIVD)
E-mail: BGIVD_Enquiries@hc-sc.gc.ca
Tel: (613) 954-6522
Fax: (613) 952-7738

Get told about the next health product recall.
Get health product recall alerts

CA$3.99/mo · cancel anytime